Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cholangiocarcinoma × RRx-001 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Lung Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Small Cell 1 Brain Neoplasms 1

Interventions

Gemcitabine 20 Cisplatin 13 pembrolizumab 5 Fluorouracil 5 pemigatinib 3 Radiotherapy 3 Drug Therapy 3 aldesleukin 2 Radiosurgery 2 Oxaliplatin 2 Nivolumab 2 Liver Transplantation 2 Leucovorin 2 Dexamethasone 2 Cholangiopancreatography, Endoscopic Retrograde 2 Carboplatin 2 Capecitabine 2 trifluridine tipiracil drug combination 1 tremelimumab 1 trametinib 1 spartalizumab 1 seribantumab 1 peginterferon alfa-2b 1 pazopanib 1 padeliporfin 1 ivosidenib 1 irinotecan sucrosofate 1 infigratinib 1 gemcitabine-oxaliplatin regimen 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02452970 2024-04-24

EPIC

EpicentRx, Inc.

Phase 2 Terminated

4 enrolled 6 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡